First-Time-in-Human Study of GSK5471713 in Adults With mCRPC
Status:
NOT_YET_RECRUITING
Trial end date:
2030-04-12
Target enrollment:
Participant gender:
Summary
This first-time-in-human study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, preliminary clinical activity, and establish the benefit/risk of GSK5471713 given as a monotherapy in mCRPC.